In a new article on PM360, Precision for Value executive vice president Bruce Leavitt provides step-by-step guidance for drug makers who find their product on one of the recently released formulary exclusion lists.

Leavitt advises manufacturers not to dismay, but instead understand what HCPs want to hear about your brand’s access—and then to respond with impactful information. An effective response can minimize the negative impact and even produce some new sources of revenue through more dynamic pull-through messaging, explains Leavitt.

To read the complete article, please click here.